AA
PRCT icon

ALPS Advisors’s Procept Biorobotics PRCT Stock Holding History

ALPS Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Sell
23,641
-3,307
-12% -$82.8K ﹤0.01% 953
2026
Q1 		$674K Buy
26,948
+3,401
+14% +$95.8K ﹤0.01% 649
2025
Q4 		$741K Buy
23,547
+1,024
+5% +$34K ﹤0.01% 649
2025
Q3 		$804K Buy
22,523
+8,854
+65% +$404K ﹤0.01% 601
2025
Q2 		$787K Sell
13,669
-1,159
-8% -$65.5K ﹤0.01% 573
2025
Q1 		$864K Buy
14,828
+4,353
+42% +$297K 0.01% 500
2024
Q4 		$843K Sell
10,475
-692
-6% -$59.1K 0.01% 526
2024
Q3 		$895K Sell
11,167
-3,610
-24% -$256K 0.01% 526
2024
Q2 		$903K Sell
14,777
-6,161
-29% -$366K 0.01% 487
2024
Q1 		$1.03M Sell
20,938
-5,060
-19% -$241K 0.01% 474
2023
Q4 		$1.09M Sell
25,998
-2,528
-9% -$86.1K 0.01% 455
2023
Q3 		$936K Sell
28,526
-4,017
-12% -$137K 0.01% 478
2023
Q2 		$1.15M Sell
32,543
-3,228
-9% -$107K 0.01% 448
2023
Q1 		$1.02M Buy
35,771
+9,513
+36% +$336K 0.01% 467
2022
Q4 		$1.09M Buy
26,258
+758
+3% +$32.5K 0.01% 452
2022
Q3 		$1.06M Buy
+25,500
New +$1.02M 0.01% 455

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ALPS Advisors's PRCT Position: Q2 2026 in Review

ALPS Advisors reduced its Procept Biorobotics (PRCT) stake by 12% in Q2 2026, selling an estimated $82.8K and leaving 23,641 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #953.

ALPS Advisors first reported a position in PRCT in Q3 2022 and has held it in 16 quarters since. The position peaked at $1.15M in Q2 2023. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • ALPS Advisors held 23,641 shares of Procept Biorobotics worth $534K as of Q2 2026.
  • ALPS Advisors sold 3,307 Procept Biorobotics shares in Q2 2026, an estimated $82.8K.
  • Procept Biorobotics made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #953 holding.
  • ALPS Advisors first reported a position in Procept Biorobotics in Q3 2022 and has held it in 16 quarters since.
  • ALPS Advisors's Procept Biorobotics position peaked at $1.15M in Q2 2023.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.